Share of Biogen Idec ( BIIB) could move higher Monday after ISI Group biotech analyst Mark Schoenebaum upgraded the stock to a buy.

"On the back of its new multiple sclerosis pill (BG-12), we now believe that Biogen can double EPS over the next 3-4 years, triple it over the next 5-6 years, and quadruple earnings over a 6-7 year horizon," said Schoenebaum in an email to clients Sunday.

Radient Pharmaceuticals ( RPC) faces a June 23 deadline to meet a list of financial requirements necessary to retain its listing on the AMEX.

--Written by Adam Feuerstein in Boston.

>To contact the writer of this article, click here: Adam Feuerstein.

>To follow the writer on Twitter, go to

>To submit a news tip, send an email to:
Adam Feuerstein writes regularly for TheStreet. In keeping with company editorial policy, he doesn't own or short individual stocks, although he owns stock in TheStreet. He also doesn't invest in hedge funds or other private investment partnerships. Feuerstein appreciates your feedback; click here to send him an email.

If you liked this article you might like

Acura Pharmaceuticals (ACUR) Stock Spikes on Development Deal with Bayer Healthcare

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Pushing The Drugs Industry Lower

3 Stocks Advancing The Drugs Industry